Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Amortization (2019 - 2025)

Quantum Biopharma's Amortization history spans 7 years, with the latest figure at -$4.7 million for Q3 2025.

  • On a quarterly basis, Amortization fell 18.24% to -$4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$20.6 million, a N/A change, with the full-year FY2024 number at $12.1 million, down 6.63% from a year prior.
  • Amortization hit -$4.7 million in Q3 2025 for Quantum Biopharma, up from -$9.8 million in the prior quarter.
  • Over the last five years, Amortization for QNTM hit a ceiling of $76.4 million in Q1 2021 and a floor of -$9.8 million in Q2 2025.
  • Historically, Amortization has averaged $29.5 million across 5 years, with a median of $21.4 million in 2023.
  • The widest YoY moves for Amortization: up 594.61% in 2025, down 195.73% in 2025.
  • Tracing QNTM's Amortization over 5 years: stood at $63.0 million in 2021, then crashed by 38.99% to $38.4 million in 2022, then plummeted by 66.39% to $12.9 million in 2023, then decreased by 6.63% to $12.1 million in 2024, then tumbled by 139.39% to -$4.7 million in 2025.
  • Business Quant data shows Amortization for QNTM at -$4.7 million in Q3 2025, -$9.8 million in Q2 2025, and $10.3 million in Q1 2025.